Theralase Technologies shares rocket on TLD-1433 clinical trial findings

Shares in Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) rocketed over 18% in Toronto as it unveiled very positive clinical trial news on its lead cancer compound TLD-1433.

The candidate is a light activated photo dynamic compound (PDC), which the firm is developing, and the trial is the first part of a Phase Ib clinical study for patients with non-muscle invasive bladder cancer (NMIBC).

First three patients…

After 90 days, the first three patients (which have remained drug resistant after the standard first line treatments) the exploratory efficacy endpoint was reached, using the maximum recommended starting dose.

“The company is ecstatic that after decades of hard work the company, in the first 3 patients treated, at the 90 day cystoscopy follow-up, at a MRSD (0.35 mg/cm2) of TLD-1433, that the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and now exploratory endpoint of efficacy have been achieved,” said Roger Dumoulin-White, Theralase’s president and chief executive.

“I wish to thank the entire Theralase board and employees, the clinical and scientific team and the Medical and Scientific Advisory Board, who have provided their knowledge, experience and worked tirelessly to make this day a reality.”

No recurrence of lesions…

Theralase noted that the first three patients demonstrated no recurrence of NMIBC lesions at the 90 day cystoscopy analysis.

One patient presented with some reddened areas of the bladder wall, which will be biopsied at a future surgical date, while further clinical analysis will be conducted on the patients according to the approved clinical protocol.

Now, a further six patients for the second part of the study, are currently being enrolled, to be treated at a therapeutic dose of the PDC (0.70 mg/cm2) for NMIBC, using its novel PDT technology.

Shares added 18.06% to $0.425.

Story by ProactiveInvestors